72180-26-8

Usage

Uses

Used in Organic Synthesis:
(S)-1-benzyl-2-methyl-4,4-difluoropyrrolidine-1,2-dicarb is used as a building block in organic synthesis for the creation of a variety of chemical compounds. Its unique structure and functional groups facilitate the synthesis of complex organic molecules, making it a valuable component in the development of new chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-1-benzyl-2-methyl-4,4-difluoropyrrolidine-1,2-dicarb serves as an intermediate in the production of various pharmaceutical compounds. Its presence in the synthesis process allows for the creation of novel drug candidates with potential therapeutic applications.
Used in Drug Development:
（s）-1-benzyl-2-methyl-4，4-difluoropyrrolidine-1，2-dicarb's unique structure and functional groups make it a promising candidate for drug development. Researchers can explore its potential as a precursor to new pharmaceuticals, leveraging its properties to design innovative treatments for various diseases and conditions.
Used in Chemical and Pharmaceutical Industries:
(S)-1-benzyl-2-methyl-4,4-difluoropyrrolidine-1,2-dicarb is utilized across chemical and pharmaceutical industries for its versatility and value. Its applications in these sectors are diverse, ranging from the synthesis of new compounds to the development of innovative pharmaceutical products. Further research and applications of （s）-1-benzyl-2-methyl-4，4-difluoropyrrolidine-1，2-dicarb may offer new insights and opportunities in these fields.

InChI:InChI=1/C14H15F2NO4/c1-20-12(18)11-7-14(15,16)9-17(11)13(19)21-8-10-5-3-2-4-6-10/h2-6,11H,7-9H2,1H3

Upstream product

• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 64187-47-9 1-benzyloxycarbonyl-4-keto-L-proline 

Relevant academic research and scientific papers

BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST

The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in fomulas (I) or a pharmaceutically acceptable salt thereof.

Discovery and synthesis of HIV integrase inhibitors: Development of potent and orally bioavailable N-methyl pyrimidones

The human immunodeficiency virus type-1 (HIV-1) encodes three enzymes essential for viral replication: a reverse transcriptase, a protease, and an integrase. The latter is responsible for the integration of the viral genome into the human genome and, therefore, represents an attractive target for chemotherapeutic intervention against AIDS. A drug based on this mechanism has not yet been approved. Benzyl-dihydroxypyrimidine-carboxamides were discovered in our laboratories as a novel and metabolically stable class of agents that exhibits potent inhibition of the HIV integrase strand transfer step. Further efforts led to very potent compounds based on the structurally related N-Me pyrimidone scaffold. One of the more interesting compounds in this series is the 2-N-Me-morpholino derivative 27a, which shows a CIC95 of 65 nM in the cell in the presence of serum. The compound has favorable pharmacokinetic properties in three preclinical species and shows no liabilities in several counterscreening assays.

(Phosphinyloxy)acid amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogues of (S)-1-[6-Amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]- L-proline

Analogues of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]- L-proline (1, SQ 29,852) in which the terminal proline residue has been replaced by a variety of substituted and heteroatom-substituted prolines, N-arylglycines, N-cycloalkylglycines, and bicyclic amino acids have been synthesized and evaluated as inhibitors of angiotensin converting enzyme in vitro an in vivo. In general, the addition of lipophilic substituents to the 4-position of proline of the parent phosphate 1 resulted in substantial increases in vitro activity. The largest improvements were observed in the case of cis-benzyl (36-fold) and dithioketal (24-fold) analogues 2r and 2x, respectively. These enhancements of in vitro activity were accompanied by modest increases (2-3.5-fold) in in vivo (iv) activity. Among the various terminal amino acid replacements examined in this study, the indoline-based analogue 2i was by far the most potent compound on iv administration in the normotensive rat.